Gene · 3702
Papers2,789
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,101 to 1,120 of 2,789
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients. | Int J Cancer | 2021 | 32683672 | PubTator, text mining | PubMed |
| BTK/ITK dual inhibitors: Modulating immunopathology and lymphopenia for COVID-19 therapy. | J Leukoc Biol | 2021 | 32640487 | PubTator, text mining | PubMed |
| Tape strips from early-onset pediatric atopic dermatitis highlight disease abnormalities in nonlesional skin. | Allergy | 2021 | 32639640 | PubTator, text mining | PubMed |
| ITK deficiency presenting as autoimmune lymphoproliferative syndrome. | J Allergy Clin Immunol | 2021 | 32628964 | PubTator, text mining | PubMed |
| PRL3 enhances T-cell acute lymphoblastic leukemia growth through suppressing T-cell signaling pathways and apoptosis. | Leukemia | 2021 | 32606318 | PubTator, text mining | PubMed |
| Lethal Infectious Diseases as Inborn Errors of Immunity: Toward a Synthesis of the Germ and Genetic Theories. | Annu Rev Pathol | 2021 | 32289233 | PubTator, text mining | PubMed |
| Combining ibrutinib and checkpoint blockade improves CD8+ T-cell function and control of chronic lymphocytic leukemia in Em-TCL1 mice. | Haematologica | 2021 | 32139435 | PubTator, text mining | PubMed |
| Turning liabilities into opportunities: Off-target based drug repurposing in cancer. | Semin Cancer Biol | 2021 | 32044472 | PubTator, text mining | PubMed |
| Promises and pitfalls of targeted agents in chronic lymphocytic leukemia. | Cancer Drug Resist | 2020 | 35582452 | PubTator, text mining | PubMed |
| Novel method to identify group-specific non-catalytic pockets of human kinome for drug design. | RSC Adv | 2020 | 35494619 | PubTator, text mining | PubMed |
| MicroRNA expression integrated analysis and identification of novel biomarkers in small cell lung cancer: a meta-analysis. | Transl Cancer Res | 2020 | 35117700 | PubTator, text mining | PubMed |
| Structural and biophysical insights into the mode of covalent binding of rationally designed potent BMX inhibitors. | RSC Chem Biol | 2020 | 34458764 | PubTator, text mining | PubMed |
Tissue Treg Secretomes and Transcription Factors Shared With Stem Cells Contribute to a Treg Niche to Maintain Treg-Ness With 80% Innate Immune Pathways, and Functions of Immunosuppression and Tissue Repair. | Front Immunol | 2020 | 33613572 | PubTator, text mining | PubMed |
| Monogenic Immune Diseases Provide Insights Into the Mechanisms and Treatment of Chronic Graft-Versus-Host Disease. | Front Immunol | 2020 | 33613511 | PubTator, text mining | PubMed |
| The Role of T Cell Receptor Signaling in the Development of Type 1 Diabetes. | Front Immunol | 2020 | 33603744 | PubTator, text mining | PubMed |
| Microclusters as T Cell Signaling Hubs: Structure, Kinetics, and Regulation. | Front Cell Dev Biol | 2020 | 33575254 | PubTator, text mining | PubMed |
| Germinal Center Cells Turning to the Dark Side: Neoplasms of B Cells, Follicular Helper T Cells, and Follicular Dendritic Cells. | Front Oncol | 2020 | 33520702 | PubTator, text mining | PubMed |
| The Bruton's Tyrosine Kinase Inhibitor Ibrutinib Impairs the Vascular Development of Zebrafish Larvae. | Front Pharmacol | 2020 | 33519491 | PubTator, text mining | PubMed |
| Recent developments in anticancer kinase inhibitors based on the pyrazolo[3,4-d]pyrimidine scaffold. | RSC Med Chem | 2020 | 33479617 | PubTator, text mining | PubMed |
| The Role of TIM-3 in Hepatocellular Carcinoma: A Promising Target for Immunotherapy? | Front Oncol | 2020 | 33425759 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3702/papers?page=56